股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 281,250 | | | RMB | | 281,250 | | 本月底結存 | | | 27,834,510 | RMB | | 1 RMB | | 27,834,510 | | 2. 股份分類 | 普通股 ...

本月底法定/註冊股本總額： RMB 360,874,970 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 281,250 | | | RMB | | 281,250 | | 本月底結存 | | | 27,834,510 | RMB | | 1 RMB | | 27,834,510 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - The article discusses the key deployments in the 2023 Central Document No. 1, focusing on agricultural modernization through technological innovation and the development of new productive forces in agriculture [5][6][7]. Group 1: Key Deployments in Agricultural Technology Innovation - The document emphasizes strengthening integrated innovation by enhancing the overall effectiveness of the agricultural technology innovation system, promoting enterprise-led innovation, and focusing on key areas such as seeds and agricultural machinery [5]. - It highlights the expansion of application scenarios through modern information technology and biotechnology, showcasing the significant role of agricultural drones and artificial intelligence in transforming agricultural practices [6]. - The document stresses the importance of promoting the transformation of agricultural technology achievements to address practical issues faced by farmers, ensuring that innovations reach rural areas effectively [7]. Group 2: Agricultural Bio-Manufacturing Paths Worth Noting - The article identifies high-value utilization of agricultural by-products, such as straw, as a key focus, indicating a shift from mere utilization to profitable applications [8]. - It discusses the potential of synthetic biology to enhance agricultural productivity by producing essential proteins and bio-fertilizers, thereby reducing reliance on chemical fertilizers [10]. - The development of new agricultural applications, including biodegradable materials and bio-pesticides, is highlighted as a means to promote green transformation in agriculture [11]. Group 3: Market Overview of Agricultural Bio-Manufacturing - As of February 9, 2025, there are 161 companies in the A-share market related to the "synthetic biology" concept, with a total market value of approximately 1.69 trillion yuan, averaging 10.5 billion yuan per company [15]. - The agricultural bio-manufacturing sector includes around 20 companies focusing on areas such as animal vaccines and feed additives, indicating a gradual industrial application of synthetic biology in agriculture [17]. - Key companies in this sector are noted for their focus on replacing feed, plant breeding, bio-pesticides, and precision farming, showcasing the diverse applications of synthetic biology in agriculture [17].

Summary of Key Points Core Viewpoint - Morgan Stanley has reduced its stake in Kelaiying (06821) by 7800 shares at a price of HKD 80.8366 per share, totaling approximately HKD 630,500, resulting in a new holding of about 1.6627 million shares, representing 5.97% of the company [1]. Group 1 - On January 28, Morgan Stanley sold 0.78 million shares of Kelaiying [1]. - The sale price per share was HKD 80.8366 [1]. - The total amount from the sale was approximately HKD 630,500 [1]. Group 2 - After the reduction, Morgan Stanley's remaining shares in Kelaiying are approximately 1.6627 million [1]. - The new holding percentage of Morgan Stanley in Kelaiying is 5.97% [1].

Group 1 - Morgan Stanley reduced its stake in Kelaiying (002821) (06821) by 0.78 million shares at a price of 80.8366 HKD per share, totaling approximately 630,500 HKD [1] - After the reduction, Morgan Stanley's latest holding is approximately 1.6627 million shares, representing a holding percentage of 5.97% [1]

智通财经APP获悉，香港联交所最新数据显示，1月28日，摩根大通减持凯莱英(06821)0.78万股，每股 作价80.8366港元，总金额约为63.05万港元。减持后最新持股数目约为166.27万股，持股比例为5.97%。 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

Investment Rating - The report maintains an "Outperform" rating for the industry [1] Core Insights - The small nucleic acid drug market is experiencing robust growth, transitioning from technology validation to accelerated commercialization, with a global market size increasing from $2.7 billion in 2019 to $4.6 billion in 2023, and projected to reach $45.7 billion by 2033, reflecting a CAGR of 26.08% [2][39] - The small nucleic acid CXO sector is benefiting from technological breakthroughs and commercialization acceleration, establishing a comprehensive CRDMO service system [2] - Key players in the small nucleic acid field include CROs with core technologies and rich project experience, such as Chengdu XianDai and Kanglong Chemical, and CDMOs with leading production capabilities like WuXi AppTec and Kailai Ying [2] Summary by Sections 1. Small Nucleic Acid Drugs - Small nucleic acid drugs encompass various types, including ASO, siRNA, and aptamers, which target gene expression for disease treatment [11][12] - These drugs offer advantages such as shorter development cycles, broad therapeutic areas, sustained efficacy, and higher success rates compared to traditional drugs [15][16] 2. Market Expansion and BD Activity - The small nucleic acid market is expanding, with significant BD transactions occurring, including a $9 billion collaboration between Wobang Pharmaceutical and Novartis, and a $2 billion platform authorization between Rebio and Boehringer Ingelheim [48] - Domestic companies are actively developing drugs targeting hyperlipidemia, hypertension, and hepatitis B, with notable progress in clinical stages [45][47] 3. CXO Empowerment in Small Nucleic Acid R&D - The CXO industry is crucial for supporting the R&D and production of small nucleic acid drugs, with a focus on enhancing delivery technologies and chemical modifications to improve drug stability and efficacy [22][26]

Group 1 - Norges Bank increased its stake in Kailaiying (06821.HK) by purchasing 99,700 shares at an average price of HKD 80.6683 per share, amounting to approximately HKD 8.0426 million [1] - Following this transaction, Norges Bank's total shareholding in Kailaiying rose to 4.2353 million shares, increasing its ownership percentage from 14.86% to 15.22% [1]

Group 1: Macro Economic Insights - The Federal Reserve maintained interest rates in the range of 3.5%-3.75% during the January FOMC meeting, indicating a stable economic expansion in the U.S. [5][6] - The labor market's downward trend and inflation risks have eased, suggesting that maintaining stable interest rates is the best choice for the short term [7][8] - Market reactions post-FOMC meeting showed little change in risk appetite, with the Dow Jones and Nasdaq indices experiencing slight increases [8] Group 2: Industrial Profit Insights - In December 2025, industrial profits for large-scale enterprises grew by 0.6% year-on-year, marking a return to positive growth after three consecutive years of decline [10][11] - The profit structure within the industrial sector is showing signs of divergence, with the equipment manufacturing sector becoming a significant driver of profit growth [13] - High-tech manufacturing profits increased by 13.3% year-on-year, significantly outpacing the average growth of all industrial sectors [13] Group 3: Pre-prepared Food Industry - The Chinese government is drafting national standards for pre-prepared foods to enhance consumer protection and industry quality [25][26] - The introduction of these standards is expected to raise compliance costs for smaller companies, leading to a market reshuffle favoring larger, established firms [27][28] - As industry standards improve, leading companies are likely to benefit from enhanced brand trust and market share [29] Group 4: Chemical Industry Developments - The Ministry of Ecology and Environment is pushing for the exit of outdated capacity in the chlor-alkali industry, particularly in PVC production, due to environmental concerns [31][32] - The implementation of the Minamata Convention will increase production costs for companies using mercury-based processes, accelerating the exit of less competitive firms [33] - Beneficiaries of these changes include companies like Xinjiang Tianye and Zhongtai Chemical, which are better positioned to adapt to the new regulatory environment [34] Group 5: Medical Industry Insights - Kailaiying, a leading small molecule CDMO, is transitioning towards a dual business model that includes emerging sectors like peptides and small nucleic acids, showing strong growth potential [35][36] - The company is expanding its peptide production capacity significantly to meet the rising demand for GLP-1 drugs, positioning itself favorably in a high-growth market [36] - The overall investment environment in the healthcare sector is improving, which may lead to increased demand for CDMO services [37]